Landscape of NcRNAs involved in drug resistance of breast cancer.
Clin Transl Oncol
; 25(7): 1869-1892, 2023 Jul.
Article
em En
| MEDLINE
| ID: mdl-37067729
Breast cancer (BC) leads to the most amounts of deaths among women. Chemo-, endocrine-, and targeted therapies are the mainstay drug treatments for BC in the clinic. However, drug resistance is a major obstacle for BC patients, and it leads to poor prognosis. Accumulating evidences suggested that noncoding RNAs (ncRNAs) are intricately linked to a wide range of pathological processes, including drug resistance. Till date, the correlation between drug resistance and ncRNAs is not completely understood in BC. Herein, we comprehensively summarized a dysregulated ncRNAs landscape that promotes or inhibits drug resistance in chemo-, endocrine-, and targeted BC therapies. Our review will pave way for the effective management of drug resistance by targeting oncogenic ncRNAs, which, in turn will promote drug sensitivity of BC in the future.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
RNA Longo não Codificante
Limite:
Female
/
Humans
Idioma:
En
Revista:
Clin Transl Oncol
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
China
País de publicação:
Itália